Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Tirofiban May Cut Early Worsening After Acute Ischemic Stroke

News Conference News ISC 2024

Tirofiban May Cut Early Worsening After Acute Ischemic Stroke

February 13, 2024

ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy

News Conference News ESOC 2023

ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy

May 25, 2023

FLASH: PE Patients Show Ongoing Clinical, QoL Gains With Thrombectomy

News Conference News SCAI 2023

FLASH: PE Patients Show Ongoing Clinical, QoL Gains With Thrombectomy

May 21, 2023

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

News Conference News AHA 2022

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

November 01, 2022

No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3

News Conference News HFSA 2022

No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3

Yael L. Maxwell

October 07, 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

News Conference News TCT 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

September 18, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

Ischemic Stroke Risk Highest Early After COVID-19 Diagnosis

News Conference News ISC 2022

Ischemic Stroke Risk Highest Early After COVID-19 Diagnosis

February 17, 2022

CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy

News Conference News ISC 2022

CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy

February 11, 2022

ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis

News Conference News ISC 2022

ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis

February 10, 2022

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

News Conference News TCT 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Yael L. Maxwell

November 09, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

Microclots Seen on OCT and Autopsy Can Inform COVID-19 Diagnostics, Care

News Conference News TCT 2020

Microclots Seen on OCT and Autopsy Can Inform COVID-19 Diagnostics, Care

October 26, 2020

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

News Conference News TCT 2020

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

Michael O'Riordan

October 14, 2020

Optimal Time to Start Anticoagulation After Stroke Remains Unclear

News Conference News ISC 2020

Optimal Time to Start Anticoagulation After Stroke Remains Unclear

February 27, 2020

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

News Conference News ESC 2018

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

Michael O'Riordan

August 28, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.